Forensic analysis of the 38 deaths of trial participants in the 6-month interim report on the clinical trial of the Pfizer/BioNTech mRNA vaccine BNT162b2: “In summary, it can be said that the decision by the US FDA and other international regulatory authorities to authorise the mRNA vaccine BNT162b2 was not a well-founded decision based on an unbiased, thorough and transparent assessment of the evidence intended to demonstrate that this vaccine meets the criteria for a ‘safe and effective’ tool for combating the COVID-19 pandemic.”